Esperion Therapeutics Inc. Common Stock (ESPR)

FairStock Score: 43/100 — MIXED

Key Financials

Strengths

• Strong Piotroski F-Score of 7/9 indicating robust financial health across profitability, leverage, and efficiency metrics
• Healthy net profit margin of 14.8% showing consistent profitability
• Revenue growth of 143.7% demonstrates strong top-line momentum

Concerns

• Altman Z-Score of -3.1 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Esperion Therapeutics Inc. Common Stock is a micro-cap healthcare company valued at $503 million. The business generates $418 million in annual revenue with a 14.8% net margin. From a quality standpoint, Esperion shows solid Piotroski F-Score of 7/9 and distressed Altman Z-Score of -3.1 warrants caution. On valuation, the stock is strong 9.0% free cash flow yield. Growth dynamics show revenue growing at 143.7% and profit growth of 390.0%. Our composite FairStock Score of 43/100 reflects below-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Esperion's 144% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer